AI has revolutionized the drug discovery and development process.
The past couple of years have seen a rapid increase in the adoption of artificial intelligence by major healthcare organizations and pharmaceutical companies. Initially, there was hesitation in investing in AI due to the unclear value proposition of its use cases. However, as technology has advanced and industry-specific applications of AI have been developed, the benefits are becoming more apparent.
In the pharmaceutical industry, artificial intelligence has opened up new possibilities for improving drug discovery and research processes. Companies like DeepMind, a subsidiary of Alphabet, have made significant strides with AI, such as the creation of the AlphaFold ecosystem. This technology allows researchers to simulate scenarios and manipulate organic models to discover new enzymatic relationships, leading to faster drug development.
Even established players like Eli Lilly are embracing AI. The partnership with BigHat Biosciences aims to accelerate drug development using AI-driven platforms like the Milliner to enhance therapeutic profiles of biologics.
AI is also making an impact on the infrastructure side of pharmaceutical companies. Companies like SkyCell are using AI for supply chain optimization and logistics management, resulting in improved efficiency and decision-making.
Integration into cloud services has been beneficial for many companies, allowing for rapid scalability and access to advanced AI capabilities. Moving pharmaceutical operations to the cloud can provide significant advantages due to the vast amount of data involved in the drug development life-cycle.
Although it is still early days for AI in the pharmaceutical industry, companies investing in this technology are likely to see improved outcomes and products for consumers in the long run.
